GEN Exclusives

More »

GEN News Highlights

More »
Nov 24, 2008

Lilly Finalizes Acquisition of ImClone Systems

  • Eli Lilly and Company completed its acquisition of ImClone Systems today. ImClone Systems is now a wholly owned subsidiary of Lilly.

    "We are excited about the successful completion of the ImClone transaction, which will broaden Lilly's portfolio of marketed cancer therapies and boost Lilly's oncology pipeline with up to three promising targeted therapies in Phase III in 2009," said John Lechleiter, Ph.D., Lilly president and CEO.

    ImClone's CEO, John Johnson, will retain his current position at ImClone after the acquisition and will report directly to Lechleiter.



GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »